Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation - PubMed (original) (raw)

. 2013 Dec;34(6):4065-71.

doi: 10.1007/s13277-013-0996-4. Epub 2013 Jul 20.

• PMID: 23873112
• DOI: 10.1007/s13277-013-0996-4

Free article

Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation

Yunze Xu et al. Tumour Biol. 2013 Dec.

Free article

Erratum in

• Tumour Biol. 2013 Dec;34(6):4101

Abstract

This study aims to investigate whether the expression of heat shock protein 90 (HSP90) is associated with the malignant pheochromocytoma (PHEO) and the effects of 17-allylamino-17-demethoxygeldanamcyin (17-AAG) on the expression of vascular endothelial growth factor (VEGF) in PHEO cell line PC12. The expression of HSP90 was investigated in 38 paraffin-embedded samples of PHEO patients using immunohistochemistry. The time and concentration effects of 17-AAG were investigated in PHEO PC12 cells. Cell proliferation was measured by MTT assay and cell counting. Apoptosis was detected by flow cytometry. Positive staining for HSP90 was found in 14 of 17 malignant (82.35%) and in 5 of 21 (23.81%) benign PHEOs. There existed a significant statistical difference between the malignant group and the benign ones (P < 0.001). 17-AAG inhibited the proliferation of HCC cells in a time- and concentration-dependent manner. The apoptosis rates of PC12 cells after treatment with 0.1 μmol/L for 6, 12, 24, and 48 h were significantly higher than that in blank control group. 17-AAG significantly downregulated VEGF-165 protein level in PC12 cells. This study has confirmed that the specific HSP90 inhibitor 17-AAG can play a therapeutic role in malignant PHEO treatment, and HSP90 qualifies as a promising new target in malignant PHEO.

PubMed Disclaimer

Similar articles

• The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
  Xu Y, Zhu Q, Chen D, Shen Z, Wang W, Ning G, Zhu Y. Xu Y, et al. Tumour Biol. 2015 Jul;36(7):5103-8. doi: 10.1007/s13277-015-3162-3. Epub 2015 Feb 15. Tumour Biol. 2015. PMID: 25682284
• Combinatorial Inhibition of mTORC2 and Hsp90 Leads to a Distinctly Effective Therapeutic Strategy in Malignant Pheochromocytoma.
  Zhang X, Gao F, Zhong S. Zhang X, et al. Curr Cancer Drug Targets. 2019;19(9):698-706. doi: 10.2174/1568009619666190206120615. Curr Cancer Drug Targets. 2019. PMID: 30727894
• Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.
  Giubellino A, Sourbier C, Lee MJ, Scroggins B, Bullova P, Landau M, Ying W, Neckers L, Trepel JB, Pacak K. Giubellino A, et al. PLoS One. 2013;8(2):e56083. doi: 10.1371/journal.pone.0056083. Epub 2013 Feb 14. PLoS One. 2013. PMID: 23457505 Free PMC article.
• [Effects of HSP90 inhibitor 17-AAG on cell cycle and apoptosis of human gastric cancer cell lines SGC-7901].
  Chen M, Xu J, Zhao J. Chen M, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2013 Feb;33(2):271-5. Nan Fang Yi Ke Da Xue Xue Bao. 2013. PMID: 23443787 Chinese.
• 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
  Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F. Babchia N, et al. Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2348-56. doi: 10.1167/iovs.07-1305. Epub 2008 Feb 15. Invest Ophthalmol Vis Sci. 2008. PMID: 18281615

Cited by

• Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy.
  Cheng W, Ainiwaer A, Xiao L, Cao Q, Wu G, Yang Y, Mao R, Bao Y. Cheng W, et al. Mol Med Rep. 2015 Aug;12(2):2451-6. doi: 10.3892/mmr.2015.3725. Epub 2015 May 4. Mol Med Rep. 2015. PMID: 25955495 Free PMC article.
• HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
  Kale Ş, Korcum AF, Dündar E, Erin N. Kale Ş, et al. Naunyn Schmiedebergs Arch Pharmacol. 2020 Feb;393(2):253-262. doi: 10.1007/s00210-019-01725-z. Epub 2019 Sep 14. Naunyn Schmiedebergs Arch Pharmacol. 2020. PMID: 31522240
• Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
  Wang C, Zhang R, Tan J, Meng Z, Zhang Y, Li N, Wang H, Chang J, Wang R. Wang C, et al. Oncol Rep. 2020 May;43(5):1491-1502. doi: 10.3892/or.2020.7537. Epub 2020 Mar 9. Oncol Rep. 2020. PMID: 32323855 Free PMC article.
• Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.
  Martucci VL, Pacak K. Martucci VL, et al. Curr Probl Cancer. 2014 Jan-Feb;38(1):7-41. doi: 10.1016/j.currproblcancer.2014.01.001. Epub 2014 Jan 15. Curr Probl Cancer. 2014. PMID: 24636754 Free PMC article. Review. No abstract available.
• The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
  Xu Y, Zhu Q, Chen D, Shen Z, Wang W, Ning G, Zhu Y. Xu Y, et al. Tumour Biol. 2015 Jul;36(7):5103-8. doi: 10.1007/s13277-015-3162-3. Epub 2015 Feb 15. Tumour Biol. 2015. PMID: 25682284

References

1. 1. Endocr Relat Cancer. 2007 Sep;14(3):569-85 - PubMed
2. 1. Neuro Oncol. 2009 Apr;11(2):109-21 - PubMed
3. 1. J Clin Endocrinol Metab. 2011 Mar;96(3):717-25 - PubMed
4. 1. Biochem J. 2008 Mar 15;410(3):439-53 - PubMed
5. 1. Biochim Biophys Acta. 2010 May;1803(5):575-83 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Springer

• Other Literature Sources

  • scite Smart Citations